Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBE2N | P61088 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL848229 | 0.91 | LMNA (0.45) | UBE2NALDH1A1HSD11B1MEN1KMT2A | |
| SCHEMBL848541 | 0.89 | PDE2A (0.45) | UBE2NALDH1A1PKMPROKR1 | |
| SCHEMBL847334 | 0.86 | MGLL (0.46) | ALDH1A1MEN1KMT2AAKR1C3 | |
| SCHEMBL847346 | 0.85 | KMT2A (0.43) | ALDH1A1MEN1KMT2AAKR1C3 | |
| SCHEMBL13552166 | 0.85 | MEN1 (0.42) | ALDH1A1MEN1KMT2AAKR1C3 | |
| SCHEMBL849916 | 0.85 | KMT2A (0.42) | ALDH1A1MEN1KMT2AAKR1C3 | |
| SCHEMBL847373 | 0.85 | MAPT (0.44) | ALDH1A1MEN1KMT2AAKR1C3 | |
| SCHEMBL849574 | 0.83 | STS (0.46) | ALDH1A1MEN1KMT2A | |
| SCHEMBL848383 | 0.83 | MEN1 (0.41) | ALDH1A1MEN1KMT2A | |
| SCHEMBL848801 | 0.83 | PTH1R (0.42) | ALDH1A1HSD11B1MEN1KMT2AAKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010126030-A1 | SPIROIMIDAZOLONE DERIVATIVE | 中外製薬株式会社 (JP) | 2010-11-04 | — | — | WO | disclosed |